Amarin Corp Plc (AMRN)

[ziploc_1]

Bus..."
Session LBS.06 - LATE BREAKING Science VI: New Frontiers in Lipid Therapy...
- Effect Of Icosapent Ethyl On Progression Of Coronary Atherosclerosis In Patients With Elevated Triglycerides (200-499mg/dl) On Statin Therapy (evaporate Study)
November 18, 2019"

The abstract of this report has been embargoed by the AHA(i.e. until the AHA meeting)...The information from this report will definitely be of vital importance for the Adcom panel to be held on Nov 14...just 4 days before the AHA meeting...Perhaps Amarin and/or the FDA could ask the AHA to remove the embargo so that the Adcom panel could make a more informed decision on Vascepa...I recognize that the AHA embargoed this study in order to interest Docs to come to the scientific sessions....In this case, the information from the Evaporate study is so important that its consideration by the FDA at the Adcom might interest even more Docs to attend the meeting.